论文部分内容阅读
目的 研究抑癌基因PTEN/MMAC1在原发性肺癌中的表达状况及其临床意义。方法应用SP免疫组织化学方法检测 4 2例手术切除肺癌标本PTEN的表达。结果①肺癌组PTEN蛋白表达总缺失率为 4 0 .4 8% ,小细胞癌表达缺失率 75 .0 0 % ,鳞癌 31.5 8% ,腺癌 33.33%。肺癌细胞的分化程度不同 ,其PTEN表达缺失存在明显差别 ,高分化和低分化肺癌PTEN表达缺失率分别为 13.33%、72 .73%(P <0 .0 1) ;鳞癌高分化组缺失率为 12 .5 0 % ,低分化组缺失率为 6 6 .6 7% (P <0 .0 5 ) ;腺癌高分化组缺失率为 14 .2 9% ,低分化组缺失率为 80 .0 0 % (P <0 .0 5 ) ;本组有淋巴结转移组与无淋巴结转移组缺失率分别为 6 6 .6 7%、2 5 .93% ,两者之间有显著差异 (P <0 .0 1) ,不同的临床分期间PTEN缺失率亦有显著的差别 ,IIIa期缺失率较高。生存时间≤ 12月 ,<6 0月、>12月 ,≥ 6 0月 ,PTEN蛋白缺失率分别为 71.4 3% ,2 5 .0 0 % ,14 .2 9% ,三者之间差异显著 (P <0 .0 5 )。结论 肺癌PTEN/MMAC1在蛋白质水平的表达缺失可能有助于其预后的判断
Objective To study the expression of tumor suppressor gene PTEN / MMAC1 in primary lung cancer and its clinical significance. Methods SP immunohistochemistry was used to detect the expression of PTEN in 42 cases of lung cancer specimens. Results ① The total loss of PTEN protein in lung cancer was 40.8%, the rate of expression of small cell carcinoma was 75.0%, that of squamous cell carcinoma was 31.5%, and that of adenocarcinoma was 33.33%. The differentiation degree of lung cancer cells was different, and there was a significant difference in the expression of PTEN. The loss rates of PTEN in well-differentiated and poorly differentiated lung cancer were 13.33%, 72.73% (P <0.01) Was 12.5%, the rate of deletion in poorly differentiated group was 66.76% (P <0.05), the rate of deletion in adenocarcinoma was 14.29%, and that in poorly differentiated group was 80%. 0 0% (P <0.05). The deletion rates of lymph node metastasis group and non-lymph node metastasis group were respectively 6.66.7% and 25.93%, there was a significant difference between the two groups (P < 0. 01). There was also a significant difference in the deletion rate of PTEN between different clinical stages, with a higher deletion rate in stage IIIa. Survival time ≤ 12 months, <6 months,> December, ≥ 60 months, PTEN protein deletion rates were 71.4 3%, 25.0%, 14.29%, the difference was significant among the three P <0. 05). Conclusions The loss of PTEN / MMAC1 protein expression in lung cancer may contribute to the prognosis